UnicoCell Biomed CoTPE:6794 -3.40%83 PB Ratio is 6.05 as of Jul. 08, 2026, which is 4% below its 10-year median of 6.31. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,225 Biotechnology companies, UnicoCell Biomed Co ranks worse than 75.67% on this metric.
The historical rank and industry rank for UnicoCell Biomed Co's PB Ratio or its related term are showing as below:
TPE:6794'
s PB Ratio Range Over the Past 10 Years
Min: 4.88 Med: 6.31 Max: 8.67
Current: 6.05
During the past 9 years, UnicoCell Biomed Co's highest PB Ratio was 8.67. The lowest was 4.88. And the median was 6.31.
TPE:6794's PB Ratio is ranked worse than 75.67% of 1225
companies
in the Biotechnology industry
Industry Median: 2.92
vs TPE:6794: 6.05
During the past 12 months, UnicoCell Biomed Co's average Book Value Per Share Growth Rate was 16.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of UnicoCell Biomed Co was 35.70% per year. The lowest was -1.40% per year. And the median was 12.50% per year.
Back to Basics: PB Ratio
UnicoCell Biomed Co (TPE:6794) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
UnicoCell Biomed Co PB Ratio Related Terms
UnicoCell Biomed Co PB Ratio Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UnicoCell Biomed Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
UnicoCell Biomed Co (TPE:6794) has a PB Ratio of 6.05 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on UnicoCell Biomed Co and its competitors. This is near median its historical median of 6.31. Over the past decade, UnicoCell Biomed Co's PB Ratio has ranged from 4.88 to 8.67. According to the industry distribution chart, UnicoCell Biomed Co ranks #927 out of 1225 companies in the Biotechnology industry, placing it in the top 75.7%.
Is UnicoCell Biomed Co's PB Ratio too high?
UnicoCell Biomed Co's current PB Ratio of 6.05 is near median its 10-year median of 6.31. Over the past 10 years, this metric has ranged from a low of 4.88 to a high of 8.67. The Biotechnology industry median PB Ratio is 2.92. UnicoCell Biomed Co's value of 6.05 is 107.2% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #927 out of 1225 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #927 out of 1225 companies for PB Ratio. This places UnicoCell Biomed Co in the lower half of its industry. The industry median PB Ratio is 2.92. UnicoCell Biomed Co's value of 6.05 is 107.2% above this benchmark. Historically, UnicoCell Biomed Co's own PB Ratio has ranged from 4.88 to 8.67 over the past decade. While the company's 10-year median is 6.31 vs. the industry median of 2.92, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.92, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current PB Ratio of 6.05 is 107.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current PB Ratio is 6.05, which is near median its own 10-year median of 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$82.30 — trading 19% below its estimated fair value. The current PB Ratio is 6.05, which is near median its 10-year median of 6.31 and 107.2% above the Biotechnology industry median of 2.92. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current PB Ratio is 6.05 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$82.30 is trading 19% below its estimated GF Value™ of NT$101.57.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
PB Ratio: 6.05 (near median its 10-year median of 6.31)
GF Value™: NT$101.57 vs. price of NT$82.30 (19% below fair value)
Industry Position: 107.2% above the Biotechnology median (#927 of 1225)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
